Brief: Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease

Ventyx Biosciences

17/06/2025 12:39

June 17 (Reuters) - Ventyx Biosciences Inc VTYX.O:

VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM ITS PHASE 2A SAFETY AND BIOMARKER TRIAL EVALUATING VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON’S DISEASE

VENTYX BIOSCIENCES INC - VTX3232 STUDY MEETS PRIMARY GOAL OF SAFETY AND TOLERABILITY

VENTYX BIOSCIENCES INC - VTX3232 SHOWS SIGNIFICANT REDUCTIONS IN NLRP3-RELATED BIOMARKERS

VENTYX BIOSCIENCES INC - VTX3232 PHASE 2 TRIAL IN OBESITY AND CARDIOMETABOLIC RISK FACTORS RESULTS EXPECTED H2 2025

Source text: ID:nGNX3SC0t2

Further company coverage: VTYX.O

 ((Reuters.Briefs@thomsonreuters.com;))